Purpose High-deductible health plan (HDHP) enrollment is expanding rapidly and might substantially increase out-of-pocket (OOP) payment burden. We examined trends in total and OOP health service expenditures overall and by insurance coverage type among women with metastatic breast cancer. Methods We used a longitudinal time series design to examine measures among 5364 women with metastatic breast cancer insured by a large US health insurer from 2004 to 2011. We measured outcomes during the 12 months after a first identified metastatic breast cancer diagnosis and required women to have at least 6 months of prior enrollment. We plotted enrollment measures and adjusted total and OOP spending. We fit trend lines using linear autoregressive models. Results Between 2004 and 2011, the percentage of women with metastatic breast cancer enrolled in employer-mandated HDHPs increased from 8 to 23% while the percentage enrolled in employer-mandated low-deductible plans (LDHPs) decreased from 69 to 37%. Over the same time period, estimated annual inflation-adjusted total health service spending among women with metastatic breast cancer whose employers only offered HDHPs or LDHPS increased from $96,899 to $104,688 (increase of $1197 per year; 95% confidence interval [CI]: $47,$2,348). Corresponding OOP spending values among these women with employer-mandated deductible levels were $4,496 and $5,151 ($91 per year trend; 95% CI -$13,$195). From 2004-2011, women in HDHPs and LDHPs had unchanged annual OOP spending, estimated at of $6642 (95% CI $6,268,$7016) and $4,247 (95% CI $3956,$4538), respectively. Thus, women in HDHPs experienced 55% (44%, 66%) more OOP spending than women in LDHP. Conclusions OOP spending among women with metastatic breast cancer and employer-mandated deductible levels was 55% higher among HDHP than LDHP members, and employer-mandated HDHP enrollment increased substantially from 2004 to 2011. Stakeholders and policymakers should design health plans that protect financially vulnerable cancer patients from high OOP costs.
Introduction
Breast cancer is the second leading cause of cancer mortality among US women, with an estimated 40,610 deaths in 2017 [1] [2] [3] . Approximately 6-10% of patients with breast cancer have metastases at diagnosis and 30-40% will eventually develop metastatic disease [4] [5] [6] [7] .
Although breast cancer-related mortality has fallen over time due to a variety of factors including improved treatment regimens, [8] advancements have come at steep costs for society and patients. From 2003 to 2008, the incremental annual total healthcare costs per patient were $5100 for inpatient services, $37,231 for outpatient care, and $1037 for prescription drugs [9] [10] [11] [12] . Data from 2000 to 2006 estimated mean cumulative total healthcare costs of $128,556 per patient over a mean duration of follow-up of about 18 months from date of chemotherapy initiation [13] . A more recent study using 2003-2009 data detected average total direct medical costs of $9788 per-patient-per-month [14, 15] .
Commercial health insurance arrangement such as highdeductible health plans (HDHPs) require potential annual out-of-pocket (OOP) spending of approximately $1000 to $6000 per person, a burden that disproportionally affects patients with expensive diseases such as cancer. Proponents of such health plans argue that HDHPs will reduce low-value care while preserving high-value care. These plans have continued to expand under the Affordable Care Act, leading to 51% of persons with employer-sponsored insurance having deductibles of $1000 or more and 23% having deductibles of $2000 or more [16] .
To our knowledge, no previous studies have examined health service and OOP spending by benefit type among women with metastatic breast cancer, a particularly vulnerable patient population with expected high costs of care. Our objective was to examine trends in insurance type arrangements, in total health service expenditures, and in OOP spending by benefit type among women with newly diagnosed metastatic breast cancer. We also sought to compare changes in spending before and after an incident metastatic breast cancer diagnosis among HDHP members versus lowdeductible health plan (LDHP) members.
Methods

Data source and study population
We drew our study population from commercially insured members in the de-identified Optum database (Eden Prairie, MN) enrolled between July 2003 and December 2012. Data comprised enrollment information and administrative (medical, pharmacy and hospitalization) claims from members of a large national health insurer in all 50 US states.
We used a previously established algorithm [17] validated by Hurvitz et al [18] to create a cohort of women with metastatic breast cancer in health insurance claims data. Figure 1 displays details of the cohort including information on inclusion and exclusion criteria, International Classification of Diseases, 9th revision (ICD-9) codes and relevant sample sizes. We included women with metastatic breast cancer, aged 25-64, who had their diagnosis of metastatic breast cancer (disease index date) on or after January 1, 2004 and on January 1, 2012 or before, were enrolled between July 2003 and December 2012 and had at least 18 months (6 months before and 12 months after their first diagnosis of metastatic breast cancer) of enrollment.
Further, we identified employers who offered only lowdeductible ($500 or less) or high-deductible ($1000 or more) health insurance plans to their employees in a given benefit year, then categorized women based on their employers' health insurance offerings. To determine employers' annual deductibles, we used a benefit variable that was available for most small employers (approximately ≤ 100 employees) and included information such as in-network and out-of-network deductible, copayment, and coinsurance amounts. For large employers, we imputed deductible levels using OOP costs among enrollees who utilized health services, an algorithm that had 96% sensitivity and 87% specificity among employers with at least 100 members.
For all analyses of spending measures, we first assessed all women with metastatic breast cancer. Our subgroups of interest were women whose employers only offered HDHPs (to reduce self-selection effects) and we compared them to women whose employers only offered LDHPs.
Outcome measures
Our primary measures included enrollment in health insurance types, total health service expenditure, and total outof-pocket (OOP) spending.
To estimate changes in enrollment in different benefit types, we calculated annual enrollment rates for each health plan type.
Total health service expenditure, a proxy measure of total utilization, estimates a health insurer's "amount allowed," the sum of health plan expenditures and patient OOP payments for all reimbursed health services (e.g., outpatient, emergency department, hospital, and pharmacy spending). This variable was standardized by the data vendor to 2012 dollars and across geography. To minimize the influence of extreme outliers, we winsorized monthly data to the top 0.1% (all numbers above zeros) of all health service spending [19] .
Total OOP spending, a measure of the economic burden of metastatic breast cancer on patients, is the sum of all patient expenditures (e.g., outpatient, emergency department, hospital and pharmacy spending) including coinsurance, copayment, and deductible amounts. To account for inflation, we adjusted for the 2012 consumer price index medical care component (MCPI) as published by the Bureau of Labor Statistics [20] . We again winsorized monthly data to the top 0.1% (all numbers above zeros) of all OOP spending [19] . We also performed sub-analyses of medical versus pharmacy OOP spending.
For annual calendar trend analyses, we first assigned each woman's monthly spending (OOP or total health service) to the calendar year in which monthly spending occurred. For analyses of spending before and after the metastatic breast cancer diagnosis, we display monthly OOP spending in the 6 months before and 12 months after the disease index date.
Covariates
Members were classified as residing in predominantly Caucasian or African American neighborhoods on the basis of living in census block groups with greater than 66% of residents of the given race. Members from census block groups that did not fall into those two categories were classified as from "mixed" racial composition neighborhoods. To generate proxy measures of socio-economic status (SES), we created previously established [21] categorical variables of census block group poverty and education levels derived from 2000 US Census reports [22] . Women were classified as residing in low SES neighborhoods if they lived in census block groups with low education (more than 25% of households with less than high school education) or low income [18] (more that 10% of households below poverty level). Women not in the low SES group were classified as higher SES. During the 6 months preceding the index metastatic breast cancer diagnosis, members were also classified as having lower morbidity if their morbidity score (Johns Hopkins ACG® System comorbidity score; ACG, version 10.0.1) was below 3.0 and higher morbidity if the ACG score was greater than or equal to 3.0 [23, 24] . The ACG score was developed on a standardized population so that a score of 1.0 represents average health. Other covariates included age category (25-39, 40-49, 50-64 years) and US region (West, Midwest, South, and Northeast).
Statistical analysis
In this retrospective cohort study, we first calculated characteristics of the study groups of interest (HDHP and LDHP members) in 2004, 2008, and 2011. Continuous measures are reported as mean (SD), categorical variables are reported as count and percentage of the total [25] .
To assess changes in enrollment, we calculated percentages of person years of women enrolled in LDHP and HDHP in the total cohort. We assess person years because women's enrollment could span calendar years and women could also be enrolled in both an LDHP and HDHP in a given calendar year if their employers transitioned in the year after her metastatic breast cancer diagnosis. We then ran a linear autoregressive model to compare statistical estimates (difference in trends) between the LDHP and HDHP groups.
To adjust annual spending per calendar year for changing population characteristics, we used generalized estimating equation (GEE) modeling with a gamma distribution, controlling for year and month of first metastatic breast cancer diagnosis, socio-economic status (SES), age, race/ethnicity, and US region. We then used marginal effects methods [26] [27] [28] to generate yearly spending amount estimates adjusted for the above covariates. In analyses restricted to the HDHP and LDHP group, we also included a benefit type variable (HDHP or LDHP) and a term interacting benefit type and calendar year. We also calculated marginal effects using this interaction term to derive adjusted spending estimates per study group per calendar year.
We then plotted the fully adjusted data points and fit trend lines using linear autoregressive models to compare statistical estimates (intercept and trend) of total health service spending and OOP spending (medical and pharmacy OOP spending) between LDHP and HDHP groups [29] .
To assess OOP spending during the period around metastatic breast cancer diagnosis, we plotted adjusted monthly OOP spending 6 months before and 12 months after the first diagnosis. To adjust for changing population characteristics, we used generalized estimating equation (GEE) modeling with a gamma distribution, controlling for the month of spending relative to the index date, deductible level, socio-economic status (SES), age, race/ ethnicity, and US region. We then used marginal effects methods [26] [27] [28] with an interaction between month relative to the disease index date and deductible group to generate monthly OOP spending amount estimates per study group per month and adjusted for the above covariates. We also calculated marginal effects using this interaction term to derive adjusted monthly spending estimates. We performed simple descriptive analyses of these adjusted monthly values, calculating the mean OOP spending for the HDHP and LDHP groups in the 6 months before and 11 months after the month of metastatic breast cancer diagnosis.
Statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc, Cary, NC) and STATA version 12.1 (Stata Corp, College Station, TX). For autoregressive models, we tested all covariates for inclusion in multivariate models, and using backward selection, we retained terms with p-values of 0.2 and under. The research protocol was approved by the Harvard Pilgrim Health Care Institutional Review Board.
Results
Baseline characteristics
A total of 5364 women with metastatic breast cancer were identified, of whom 13% died during the observation period (Table 1) . Most women were from predominantly Caucasian neighborhoods (77%), aged between 50 and 64 years (58%), from the South (45%), residing in high-SES neighborhoods (70%), and with ACG morbidity scores under 3.0 (74%) prior to metastatic breast cancer diagnosis. Our subgroups of interest comprised 3721 women whose employers offered either only HDHPs or only LDHPs. 
Changes in annual enrollment
Among all women included in the study cohort, the percentage whose employers mandated HDHPs increased significantly over time from 8% in 2004 to 23% in 2011 (Fig. 2) , an annual increase of 2% per year (95% CI 2, 3%). At the same time, the percentage whose employers offered only LDHPs decreased from 69% in 2004 to 37% in 2011 or by − 5% per year (− 6%, − 4%). 
Annual spending per calendar year
Annual spending per calendar year stratified by subgroups
Spending measures stratified by health plan type demonstrated that in 2004, women in HDHPs had estimated total health service expenditure of $100,105 ($94,512, $105,698) compared to $88,123 for women in LDHPs ($78,617, $97,628); (Fig. 4 and (40) 15 (46) 143 (42) 52 (43) 106 (38) 88 (45) (30) 111 (32) 8 (24) 87 (26) 33 (27) (26) 71 (20) 8 (24) 103 (30) 33 (27) 
OOP spending relative to first diagnosis of metastatic breast cancer
OOP spending peaked dramatically in the month of metastatic breast cancer diagnosis and was consistently higher among HDHP versus LDHP members. (Fig. 5 ) While women in LDHPs and in HDHPs paid on average inflation and marginally adjusted $151 and $281 per month, respectively, 6 months before their first diagnosis with breast cancer, their OOP spending peaked in the month of diagnosis at $945 for LDHP members and $1842 for HDHP members. Average monthly OOP spending in the year after the first diagnosis was $279 for women in LDHPs and to $441 for women in HDHPs.
Discussion
In this population-based cohort of 3721 younger commercially insured women with metastatic breast cancer in employer-mandated LDHPs and HDHPs an increasing proportion was enrolled in HDHPs, reaching 23% by 2011.
Total health service expenditure was high and increased between 2004 and 2011, while OOP spending did not increase to a statistically significant degree. When stratifying by health insurance type, we found that women in HDHPs averaged $6,642 in annual OOP spending as compared to $4247 among women in LDHPs. Thus, increasing enrollment in HDHPs combined with their high average OOP obligations implies that commercially insured women with metastatic breast cancer will increasingly face higher OOP spending. High OOP spending raises concerns regarding the financial burden of metastatic breast cancer care, especially because HDHP enrollment continues to increase rapidly [16] . Although we did not have access to women's premium payments, and thus are unable to compare the total cost sharing burden of HDHP and LDHP members, it is likely that HDHP members pay greater combined total premiums and OOP payments than LDHP members.
To our knowledge, this is the first study examining OOP spending and benefit types among younger, privately insured women with metastatic breast cancer. Our results confirm previous findings of high OOP spending in metastatic breast cancer, especially in the month of the first diagnosis [9, 14, 30, 31] . We add the unique finding that the growth of HDHPs and the trend toward employers offering only plans with high deductibles is likely to drive OOP spending increases among women with metastatic breast cancer going forward. HDHPs are intended to incentivize patients to reduce discretionary care and mitigate premium increases [32, 33] . However, patients with metastatic breast cancer are likely to exceed annual deductibles and reach out-of-pocket maximums in the peri-diagnosis period, while also facing a life-threatening disease. Thus, "value-shopping" seems less likely to play a role in utilization choices, although annual deductible and OOP maximum resets could still lead to conscientiousness about value among HDHP members with metastatic breast cancer.
Despite uncertain premium differences between HDHP and LDHP members, it is very likely that HDHP members have a higher overall cost burden, which might cause challenges to these patients in affording other important life expenses such as food, education, and housing. Health insurance premiums add substantially to the financial burden of [35] .
To put our findings into perspective, a woman with metastatic breast cancer who was enrolled in a HDHP and earned the 2011 federal minimum wage of $7.25 per hour [36] would spend 46% of her annual salary of about $14,500 to cover her average annual OOP obligations for metastatic breast cancer treatment of $6642 without spending anything else for rent, food, or other necessary services. Furthermore, the 2011 mean annual out-of-pocket spending of $6,642 represents 13% of the 2011 real median income household of $50,054 [37] .
It is important to note that OOP obligations among women we defined as in LDHPs are also substantial and could cause adverse effects. These women might also have generally reached their OOP maximum, indicating that OOP maximums are generally lower in LDHPs and emphasizng the importance of this cap in spending.
Our results add to a growing literature quantifying the extent and consequences of high out-of-pocket spending for cancer treatments, often referred to as financial distress or financial toxicity [38] [39] [40] . Nipp et al [41] showed that financial distress caused by cancer therapies caused patients to adjust their lifestyle by spending less on food or clothing or leisure activities and adopting potentially harmful strategies such as not filling prescriptions or taking less medication than prescribed [40] [41] [42] [43] [44] [45] . Further, high out-of-pocket spending for cancer treatments can often lead to personal bankruptcy [46, 47] . Ramsey et al [48] showed that "severe financial distress requiring bankruptcy protection after cancer diagnosis appears to be a factor for mortality" [48] . Wharam and collegues [49] found that mandated HDHP enrollment was associated with delayed breast cancer diagnosis and treatment.
Based on emerging evidence from HDHP studies, [28, 50] researchers have recently advocated for "populationtailored" health plans [51, 52] that seek to improve health outcomes and equity by targeting reduced OOP obligations based on rigorous evidence of a population's response to financial incentives. Our findings provide a basis for subsequent studies that could determine whether high-value care is reduced among HDHP members and whether such reductions are concentrated among vulnerable populations such as low-income women.
Our study has several limitations. First, the health insurance claims-based algorithm we used to identify metastatic breast cancer might have misclassified some women, but any misclassification is unlikely to differ by HDHP versus LDHP status. Second, our algorithm is unable to reliably distinguish between de novo metastatic breast cancer and progressed early stage cancer, conditions that might have different costs. Third, we measured health service and out-of-pocket spending as captured in claims data, which does not capture the full burden of expenses related to metastatic breast cancer such as premiums, travel spending, or lost wages. Additionally, our findings only apply to commercially insured patients. 
Conclusion
Between 2004 and 2011, an increasing proportion of commercially insured women with metastatic breast cancer were enrolled in employer-mandated HDHPs. Compared to women in LDHPs, women in HDHPs paid higher annual OOP costs --approximately $6600 --over our study period. Thus, increasing enrollment in HDHPs combined with their high average OOP obligations implies that commercially insured women with metastatic breast cancer will increasingly face higher OOP spending. HDHP membership was also associated with slightly lower total health spending compared with low-deductible enrollment, and further research should assess causes and health impacts of this finding. Stakeholders and policymakers should develop plan designs that protect financially vulnerable cancer patients from high OOP costs. 
